Results 41 to 50 of about 674,291 (325)

Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. [PDF]

, 2013
BACKGROUND: Riociguat, a member of a new class of compounds (soluble guanylate cyclase stimulators), has been shown in previous clinical studies to be beneficial in the treatment of chronic thromboembolic pulmonary hypertension. METHODS: In this phase 3,
CHEST-1 Study Group,, D'Armini, AM, Fritsch, A, Ghofrani, HA, Grimminger, F, Hoeper, MM, Jansa, P, Kim, NH, Mayer, E, Neuser, D, Simonneau, G, Wang, C, Weimann, G, Wilkins, MR   +13 more
core   +1 more source

Pulmonary hypertension associated with left-sided heart disease

Swiss Medical Weekly, 2017
Pulmonary hypertension associated with left-sided heart disease (PH-LHD) is the most common type of pulmonary hypertension. In patients with left-sided heart disease, the presence of pulmonary hypertension is typically a marker of more advanced disease,
Micha T. Maeder, Otto D. Schoch, Rebekka Kleiner, Lucas Joerg, Daniel Weilenmann, Swiss Medical Weekly   +5 more
doaj   +1 more source

Riociguat for Pulmonary Hypertension [PDF]

New England Journal of Medicine, 2013
open
Jaewon Oh, Jong Chan Youn, Seok Min Kang
openaire   +8 more sources

MicroRNA-483 amelioration of experimental pulmonary hypertension. [PDF]

, 2020
Endothelial dysfunction is critically involved in the pathogenesis of pulmonary arterial hypertension (PAH) and that exogenously administered microRNA may be of therapeutic benefit.
Bai, Liang, Chen, Shanshan, Chou, Chih-Hung, Cui, Xiaopei, Fan, Fenling, Gongol, Brendan, Gu, Mingxia, He, Ming, He, Yangyang, Huang, Hsien-Da, Jing, Zhi-Cheng, Lei, Yuyang, Li, Zhao, Malhotra, Atul, Miao, Yifei, Rabinovitch, Marlene, Shen, Yuan, Shyy, John Y-J, Wang, Xiaojian, Yan, Xiaosong, Zhang, Jiao, Zhang, Jin, Zhang, Yixin   +22 more
core   +1 more source

Pediatric Pulmonary Hypertension

Journal of the American College of Cardiology, 2013
Pulmonary hypertension (PH) is a rare disease in newborns, infants, and children that is associated with significant morbidity and mortality. In the majority of pediatric patients, PH is idiopathic or associated with congenital heart disease and rarely is associated with other conditions such as connective tissue or thromboembolic disease.
Ivy, D Dunbar, Abman, Steven H, Barst, Robyn J, Berger, Rolf M F, Bonnet, Damien, Fleming, Thomas R, Haworth, Sheila G, Raj, J Usha, Rosenzweig, Erika B, Schulze Neick, Ingram, Steinhorn, Robin H, Beghetti, Maurice   +11 more
openaire   +6 more sources

Pulmonary Hypertension [PDF]

American Journal of Respiratory and Critical Care Medicine, 2015
Pulmonary hypertension is said to occur when the mean pulmonary arterial pressure exceeds 25 mmHg at rest or 30 mmHg during exercise. There are many causes but the term Pulmonary arterial hypertension (PAH) is used to describe a rare group of illnesses that share histopathological similarities in the small muscularised pulmonary arterioles leading to ...
Ali Ataya, Johan Barretto, John Wynne
openaire   +4 more sources

Right Heart Size and Right Ventricular Reserve in Pulmonary Hypertension: Impact on Management and Prognosis

Diagnostics, 2020
Various parameters reflecting right heart size, right ventricular function and capacitance have been shown to be prognostically important in patients with pulmonary hypertension (PH).
Ekkehard Grünig, Christina A. Eichstaedt, Rebekka Seeger, Nicola Benjamin   +3 more
doaj   +1 more source

Pulmonary Hypertension Caused by Pulmonary Venous Hypertension [PDF]

Pulmonary Circulation, 2014
The effect of pulmonary venous hypertension (PVH) on the pulmonary circulation is extraordinarily variable, ranging from no impact on pulmonary vascular resistance (PVR) to a marked increase. The reasons for this are unknown. Both acutely reversible pulmonary vasoconstriction and pathological remodeling (especially medial hypertrophy and intimal ...
openaire   +4 more sources

Effects of novel muscarinic M3 receptor ligand C1213 in pulmonary arterial hypertension models. [PDF]

, 2016
Pulmonary hypertension (PH) is a complex disease comprising a pathologic remodeling and thickening of the pulmonary vessels causing an after load on the right heart ventricle that can result in ventricular failure. Triggered by oxidative stress, episodes
Ahmed, Mohamed, Al-Abed, Yousef, Coleman, Thomas, Lakshminrusimha, Satyanarayana, Patel, Hardik, VanPatten, Sonya   +5 more
core   +2 more sources

Early treatment with ambrisentan of mildly elevated mean pulmonary arterial pressure associated with systemic sclerosis: a randomized, controlled, double-blind, parallel group study (EDITA study)

Arthritis Research & Therapy, 2019
Objective The objective of this randomized, placebo-controlled, double-blind, parallel group, trial was to assess the effect of ambrisentan on mean pulmonary arterial pressure (mPAP) in patients with systemic sclerosis (SSc) and mildly elevated pulmonary
Zixuan Pan, Alberto M. Marra, Nicola Benjamin, Christina A. Eichstaedt, Norbert Blank, Eduardo Bossone, Antonio Cittadini, Gerry Coghlan, Christopher P. Denton, Oliver Distler, Benjamin Egenlauf, Christine Fischer, Satenik Harutyunova, Panagiota Xanthouli, Hanns-Martin Lorenz, Ekkehard Grünig   +15 more
doaj   +1 more source